Rennova Health's Epic Reference Labs Receives Accreditation From College of American Pathologists

WEST PALM BEACH, FL--(Marketwired - January 17, 2018) - Rennova Health, Inc. (OTCQB: RNVA), (OTCQB: RNVAW) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, that opened its first rural hospital in Oneida, Tenn. in August 2017, announces that its flagship Laboratory, EPIC Reference Labs, Inc. (EPIC) has successfully met the Laboratory Accreditation Program Standards for Accreditation from the College of American Pathologists (CAP). EPIC has been operating as a urine toxicology testing laboratory in Riviera Beach, Fla. since 2015.

Under the CAP Accreditation, EPIC has been accredited for the following testing services: All Common, Chemistry, Director/Organizational Assessment, Hematology, Immunology, Laboratory Central, Special Chemistry, Toxicology and Urinalysis. Subspecialty accreditation was also granted for Endocrinology, General Immunology, Hematology, Routine Chemistry, Toxicology, Urinalysis and Syphilis Serology.

"This accreditation is testament to the standards of quality and accuracy that we deliver to our diagnostics customers, and is evidence of the capabilities of our laboratory division staff," said Seamus Lagan, CEO of Rennova. "We believe that growth in our diagnostics business will be based on the quality of service we provide combined with payer contracts. We are pleased with our achievements in both of these areas.

"On behalf of Rennova Health, I would like to congratulate the facility's director Dr. Carlos M. Ricart for this national achievement and for the excellent service provided by his staff," Mr. Lagan added.

Rennova opened EPIC in early 2015 with a focus on standard clinical diagnostics and significant capacity for urine toxicology testing services with automated sample preparation and 10 Liquid chromatography-mass-spectrometry (LC-MS) machines in place. This facility enabled the Company to combine the work of three Florida-based labs into one and created numerous efficiencies in doing so. The laboratory has secured a number of in-network contracts with payers over the past two years and has 13 contracts in place with various payers including a national contract with United Healthcare. It also is registered with Medicaid in 26 states.

In addition to offering its proprietary electronic health records (EHR) and revenue cycle management services, Rennova offers its customers a complete integration of its suite of services.

The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal to or more stringent than the government's own inspection program. During the CAP accreditation process, which is designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory's records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.

About Rennova Health, Inc.
Rennova provides industry-leading diagnostics and supportive software solutions to healthcare providers, delivering an efficient, effective patient experience and superior clinical outcomes. Through an ever-expanding group of strategic brands that work in unison to empower customers, we are creating the next generation of healthcare. For more information, please visit www.rennovahealth.com.

Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company's most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.